Samsung Biologics has made a $1.8 billion all-cash offer to acquire Switzerland's PolyPeptide Group, a leader in peptide-based pharmaceutical ingredients. This acquisition aims to diversify Samsung's portfolio by entering the fast-growing peptide therapeutics market, especially targeting obesity and diabetes treatments like GLP-1 drugs. The deal, expected to close by year-end, is the largest biopharmaceutical M&A in South Korea's history and will expand Samsung's global reach with PolyPeptide's facilities in Europe, the US, and India. This move positions Samsung Biologics to meet rising demand for innovative weight-loss and diabetes therapies.
Zealand Pharma executed transactions to repurchase 205,000 shares during week 29 (July 13-17, 2026) as part of its ongoing share buy-back program authorized for up to DKK 1.3 billion. The total shares repurchased under the program now amount to 1,994...
State Street saw its price target raised to $200 by Evercore ISI, reflecting an 8.7% potential upside, following strong Q2 financial results. The company reported earnings of $3.65 per share, beating estimates, and revenue grew 17% year-over-year to ...
Hut 8 has secured a $9.8 billion, 15-year lease to fully commercialize its 1-gigawatt Beacon Point AI data center campus in Texas, expanding its contracted IT capacity to 949 MW. This marks a strategic shift from cryptocurrency mining to AI infrastru...
Saputo Inc. will hold its 2026 Annual General Meeting of Shareholders on August 7 in a hybrid format, allowing both in-person and online participation. The company will release its fiscal 2027 first quarter results on August 6 after market close, fol...
Construction activity in Saskatchewan is expected to grow steadily until 2035, mainly driven by a strong increase in residential building and renovations. Non-residential construction will see moderate growth with fluctuations tied to major project t...
